16th congress of the European Association for Clinical Pharmacology and Therapeutics

Precision Clinical Pharmacology

Preliminary program

Saturday 8 June 2024

• 09:00 - 18:30
  Registration
• 10:00 - 12:00
  Seminar: ‘How to pick the right dose: Basic concepts of using PBPK modeling in special populations’

  • 10:00 - 10:10
    Welcome
  • 10:10 - 10:40
    LE 1: PK changes in paediatric and pregnancy
  • 10:40 - 11:10
    LE 2: Basic concepts of PBPK modelling + demo
  • 11:10 - 11:30
    Short break to stretch legs
  • 11:30 - 12:00
    LE 3: PBPK in special populations
• 12:00 - 13:00
  Lunch (included)
• 13:00 - 16:00
  Workshop: ‘How to pick the right dose: Hands-on experience with PBPK modelling in special populations’ (PRE-REGISTERED)

  • 13:00 - 13:50
    Create groups, start software, resolve technical issues
  • 13:15 - 14:00
    Hands-on A: Paediatric PBPK modelling
  • 14:00 - 14:20
    Hands-on A: Plenary discussion
  • 14:20 - 14:30
    Coffee break
  • 14:30 - 15:15
    Hands-on B: Pregnancy PBPK modelling
  • 15:15 - 15:35
    Hands-on B: Plenary discussion
  • 15:35 - 15:45
    Wrap up
• 13:00 - 16:30
  Pre-meeting clinical pharmacologists in training and early career

  • 13:00 - 13:45
    Toxicology from Rotterdam, the biggest harbour in Europe
  • 13:45 - 14:45
    Update EACPT early career survey
  • 14:45 - 15:05
    Planetary health in education in prescribing Joost Piët
  • 15:05 - 16:30
    Quiz and speed dating early career clinical pharmacologists
• 16:30 - 18:30
  Congress Reception

Sunday 9 June 2024

• 08:00 - 09:00
  Registration
• 09:00 - 10:15
  Plenary Session 1 | The WHO 6-Step concept, precision medicine & genotyping

  WHO Step: 1-6

  • 09:00 - 09:15
    Explanation of research agenda: advanced 6-step

    Gerard Rongen
  • 09:15 - 09:30
    Drug shortages - how to tackle this multi-headed monster

    Ton de Boer
  • 09:30 - 09:45
    Precision targeting and target modification in academia

    Willem Mulder
• 10:15 - 10:35
  Poster Pitches

  WHO Step: 1-2

  Abstracts

  Angiomorphometric Of Breast Carcinoma and Prognostic Biomarkers

  Submitted by: MUNA DAWOOD BAWAZEER

  Evaluating the Efficacy of Alpha Lipoic Acid in the Treatment of Thermal Ocular Burns: A Comparative Histopathological Study

  Submitted by: Yasemen Adalı

  AZITHROMYCIN AS HOST-DIRECTED THERAPY FOR PULMONARY TUBERCULOSIS

  Submitted by: Bart Dekkers

  Variability in Perfusion Conditions and Set-Up Parameters Used in Ex Vivo Human Placenta Models: A Literature Review

  Submitted by: Femke Anna Elzinga

  Influence of carob extract (Ceratonia siliqua L.) on metabolic disorder markers in laboratory rats

  Submitted by: Nikola Denda

  Effect of Epigallocatechin Gallate on Neutrophil Infiltration-Related Markers in Reperfusion Injury

  Submitted by: Furkan Toksözlü

  EVALUATION OF FLUCLOXACILLIN PHARMACOKINETICS IN PEDIATRIC AND ADULT INTENSIVE CARE PATIENTS

  Submitted by: Ymke Van der Velde

  Salivary microbiome as a prognostic biomarker for asthma attacks in children: results from a machine-learning approach in the SysPharmPediA study

  Submitted by: Shahriyar Shahbazi Khamas

  Effects of alcohol combined with energy drinks in men and women in an experimental binge drinking pattern

  Submitted by: Olga Hladun

  The effect of dupilumab on the immunological mechanisms driving chronic rhinosinusitis

  Submitted by: Patricia Jaeger

• 10:35 - 11:20
  Coffee Break
• 11:20 - 13:00
  Plenary Session 2 | Drug repositioning, precision targeting & target modification

  WHO Step: 1-2

  • 11:20 - 11:50
    European network to facilitate research on Drug-repurposing and its implementation

    Donald Lo
  • 12:20 - 13:00
    Lifetime achievement award winner

    Pierre Marquet
• 13:00 - 14:00
  Lunch Poster Session

  WHO Step: 1-2

• 14:00 - 16:00
  Parallel Sessions 1-2-3

  WHO Step: 1-2

  • 14:00 - 16:00
    Parallel 1

    Abstracts

    2-methoxyestradiol in chemotherapy of skin cancers bound in graphene nanoplatelets-based hybrids and used as a therapeutic system with regulated bioavailability

    Submitted by: Tomasz Bączek

    The anticonvulsant effect of mitocurcumin in the treatment of epilepsy

    Submitted by: Alin Dumitru Ciubotaru

    Acute effects of two synthetic pyrovalerone-type cathinones compared to cocaine

    Submitted by: Clara Pérez-Mañá

    Towards precision medicine: inflammatory nasal epithelial transcriptomic profiles in patients suffering from long COVID

    Submitted by: Nadia Baalbaki

    Beyond Anticoagulation: A Pharmaco-proteomic Exploration of the Pleiotropic Mechanisms of Direct Oral Anticoagulants

    Submitted by: Natalia Atzemian

    Assessing the Protective Role of All-Trans Retinoic Acid in Cisplatin-Induced Pulmonary Toxicity

    Submitted by: Yasemen Adalı

  • 14:00 - 16:00
    Parallel 2

    Abstracts

    Phase 0 microdose studies in early clinical development

    Submitted by: Ad Roffel

    Lysozyme based spray in treatment of oral mucositis due to radiotherapy

    Submitted by: Dzenana Huduti

    MB09, a candidate denosumab biosimilar: bioequivalence demonstration in a Phase I study in healthy subjects

    Submitted by: Javier Queiruga-Parada

    The natural marine product fucoidan sensitizes breast tumours to anti-PD-1 immunotherapy in vivo

    Submitted by: Maha Ramadan Amin Abdollah

    Physiologically-based pharmacokinetic modeling of uridine 5'diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

    Submitted by: Ymke Van der Velde

    Metabolism of paracetamol differs following oral and intravenous administration

    Submitted by: Cedric Lau

  • 14:00 - 16:00
    Parallel 3

    • 14:00 - 16:00
      Physico-chemical characteristics of hepatotoxic drugs - and how to predict them (using machine learning)

      Felix Hammann
    • 14:00 - 16:00
      DILI: a daily challenge

      Haithem Chtioui
    • 14:00 - 16:00
      DILI consortium

      Gerd Kullak
    • 14:00 - 16:00
      Drug-induced liver injury: present and future

      Jamal Bouitbir
• 16:00 - 16:30
  Tea Break
• 16:30 - 18:00
  Parallel Sessions 4-5

  WHO Step: 1-2

  • 16:30 - 18:00
    Parallel 4

    • 16:30 - 18:00
      Translational Pharmacology

      EPHAR and EACPT (winners of Young translational investigator awards)
  • 16:30 - 18:00
    Parallel 5

    Abstracts

    Multi-country survey on motivations and needs of healthy volunteers during clinical trials in European Clinical Research Units (CRUs)

    Submitted by: Thijs Van Iersel

    Roadmap for the accelerated development and clinical translation of fluorescent tracers using adalimumab-680LT

    Submitted by: Henrik Huizinga

    Development and validation of an ex vivo human placenta perfusion model

    Submitted by: Aida Hadzihasanovic

    Changes of the Tumor Micro-environment after Topical Chlormethine in Early-stage Mycosis Fungoides using Interstitial Fluid Immunophenotyping

    Submitted by: Selinde Wind

• 17:00 - 19:30
  Satellite 1 Education Working Group

  • 17:00 - 19:30
    Education Workin Group/Revised WHO GGP, use of 6 step in education

    Michiel van Agtmaal

Monday 10 June 2024

• 07:30 - 08:00
  Early Morning Run

  On Monday 10 June, why not get your congress day off to a sportive start and join the early morning run! It’s a great way to combine a bit of sightseeing with an invigorating jog. The route takes in Rotterdam’s most iconic bridges.

  Time 07.30 start
  Address Depart from the Doelen

  Route The Doelen – Markthal – Maasboulevard – Erasmusbrug – Noordereiland – Willemsbrug – The Doelen (5km)

• 08:00 - 08:50
  Meet the experts | Formulations in special populations & PK-PD in drug evaluation

  WHO Step: 3-4

  • 08:00 - 08:50
    Meet the expert 1
  • 08:00 - 08:50
    Meet the expert 2
  • 08:00 - 08:50
    Meet the expert 3
• 08:00 - 09:00
  Registration
• 09:00 - 10:00
  Plenary Session 3 | Innovative trials & PK-PD in precision pharmacology

  WHO Step: 3-4

  • 09:00 - 09:30
    -

    General assembly
  • 09:30 - 10:00
    Innovative CT-designs: how to bridge trials to practice; ACT-EU

    Peter Arlett
• 10:00 - 10:10
  Poster Pitches

  WHO Step: 3-4

  Abstracts

  Interest of pharmacogenetics in statin-associated muscle symptoms: reappraisal using meta-epidemiological approach

  Submitted by: Arthur Gougeon

  Neuropsychological assessment of elderly people after RSV vaccination: study protocol

  Submitted by: Aikaterini Stravoravdi

  Population pharmacokinetics of benzathine penicillin G in pregnant Ethiopian women with syphilis

  Submitted by: Eshetie Birru

  PREDICTIONS OF IMATINIB PHARMACOKINETICS IN PREGNANT WOMEN BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING

  Submitted by: Paola Mian

• 10:10 - 10:30
  Coffee Break
• 10:30 - 12:30
  Parallel Sessions 6-7-8

  WHO Step: 3-4

  • 10:30 - 12:30
    Parallel 6

    • 10:30 - 12:30
      Improving clinical drug development success by transparency of clinical trial progress & outcome

      Florian Naudet

    Abstracts

    Vibration of effects resulting from network geometry in mixed-treatment comparisons: a case study on network meta-analyses .

    Submitted by: Constant VINATIER

    Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised trial

    Submitted by: Kari Tikkinen

    Safety and efficacy of intracavernosal platelet rich plasma versus platelet poor plasma in erectile dysfunction: A randomized clinical trial (PREPED)

    Submitted by: Gustavo Adolfo Centeno Soto

    Does conducting clinical trials at home improve participant representativeness?

    Submitted by: Amos De Jong

    The nature of uncertainties on the benefit-risk balance of anticancer medicines at initial marketing authorisation in the European Union

    Submitted by: Anne (A.C.) Taams

    A Proof-Of-Concept Study To Explore The Role Of Neostigmine In Snake Bite In Tertiary Care Hospital In North India

    Submitted by: Bikash Medhi

  • 10:30 - 12:30
    Parallel 7

    • 10:30 - 12:30
      Technology-driven approaches to improving drug safety in clinical practice

      Munir Pirmohamed

    Abstracts

    Assessing validity of Event-Free-Survival as a surrogate endpoint for Overall Survival in oncohaematologic trials

    Submitted by: Victoria Aniyar

    A Look at Surrogate Endpoints: Onco-Haematology Medicines under Conditional Marketing Authorization (2006-2022)

    Submitted by: Lucía Arellano

    Implementation of a smartphone app to guide outpatient clinic patients in discontinuing inappropriate PPI use: an open randomized superiority trial

    Submitted by: Lieke Koggel

    Are academic Sponsors prepared for clinical trials’ transition to CTIS? Situation in Spain

    Submitted by: Judit Pich

    Characterisation of evidence for the correlation of clinical outcomes with surrogate endpoints used in marketing authorisation

    Submitted by: Renske Grupstra

    Therapeutic Potential of Psychedelic Substances in the Treatment of Psychiatric Disorders

    Submitted by: Eleftheria Vlachou

  • 10:30 - 12:30
    Parallel 8

    • 10:30 - 12:30
      Precision Pharmacology in children: ontogenesis and TDM

      Population pharmacokinetic analysis of drugs for pulmonary hypertension and estimation of plasma concentrations in pediatric and adult patients

      Submitted by

      Motoyasu Miura

      Description of tacrolimus pharmacokinetics in pediatric liver transplant receipts during the first month after transplantation

      Submitted by

      Paola Mian

      External validation of risperidone population pharmacokinetics model and therapeutic window in children with autism spectrum disorder

      Submitted by

      Kathalijne Bruens

      Performance evaluation of 23 vancomycin pediatric population pharmacokinetic models for the estimation of the AUC based on trough concentrations

      Submitted by

      Stef Schouwenburg

      Association of corticosteroid inhaler with saliva microbiota composition in moderate-severe pediatric asthma

      Submitted by

      Amir Hossein Alizadeh Bahmani

      Multicenter prospective validation of an individualized model-based dosing regimen for vancomycin in preterm and term neonates

      Submitted by

      Swantje Völler
• 12:30 - 14:00
  Lunch Poster Session

  WHO Step: 3-4

• 14:00 - 16:00
  Parallel Sessions 9-10-11

  WHO Step: 4-5

  • 14:00 - 16:00
    Parallel 9

    • 14:00 - 16:00
      Sex or gender differences in drug utilization
    • 14:00 - 16:00
      Sex or gender differences in adverse drug events

      Diana Rydberg
    • 14:00 - 16:00
      Sex or gender differences in adverse drug events

      Diana Rydberg
  • 14:00 - 16:00
    Parallel 10

    • 14:00 - 16:00
      Effective, innovative trial designs in cardiovascular drug development

      Tabassome Simon

      Low-intervention clinical trials in Spain: a 10-year review

      Submitted by

      Claudia E. Delgado-Espinoza

      The effect of switching the H1-antagonist clemastine to cetirizine in paclitaxel premedication regimens ‘The H1-SWITCH study’.

      Submitted by

      Ruben Malmberg

      Pharmacokinetic/pharmacodynamic target attainment of commonly used ß-lactam antibiotics in hospitalized older patients using current dosing regimens

      Submitted by

      Arnaud De Clercq

      Nocturnal safety of daridorexant (QUVIVIQ®) in healthy elderly subjects, a dual orexin receptor antagonist

      Submitted by

      Massimo Magliocca

      Efficiency gains from Bayesian designs in randomised clinical trials: a case study in oncology

      Submitted by

      Borja Garcia
  • 14:00 - 16:00
    Parallel 11 | Dose Individualization of Biologics to Improve Patient Outcome: a Joint ACCP-EACPT Symposium

    Donald Mager

    • 14:00 - 14:20
      Opening & Clinical pharmacology considerations of biologics: Fundamentals and principles

      Donald Mager
    • 14:25 - 14:45
      Model informed precision dosing of targeted therapies in oncology: challenges and opportunities in clinical practice
    • 14:50 - 15:10
      Size descriptors and disease biomarkers for dose individualization of biologicals in adult and pediatric SCT: a prospective clinical trial to improve outcome
    • 15:15 - 15:35

    Abstracts

    Development of an online tool for the management of drug-drug interactions within the MISSION clinical trial

    Submitted by: David Burger

    Pharmacogenetic guided drug therapy - how to deal with phenoconversion in polypharmacy?

    Submitted by: Julia Stingl

• 16:00 - 16:30
  Tea Break
• 16:30 - 17:30
  Plenary Session | Reducing the number-to-treat

  WHO Step: 3-4

• 17:30 - 18:30
  Satellite 4 British Pharmacological Society
• 17:30 - 18:30
  Satellite 5 EACPT Council Meeting
• 19:30 - 23:30
  Congress Dinner

Tuesday 11 June 2024

• 07:30 - 08:30
  Early Morning Bootcamp

  On Tuesday 11 June, we start the day with a powerful kick off! In one of the most beautiful parks of Rotterdam, the park near the Euromast. Join us for a forty minutes workout and be ready for your next day at the congress. ‘We are in this together!’ 

  Time 07.30 – 08.30
  Address Euromast, Parkhaven 20, 3016 GM Rotterdam

• 07:30 - 08:30
  Early Morning Yoga

  With Morning Yoga, you will start your day in an energetic way. And you will notice the positive effect throughout the day. Join us for a 30 minutes yoga meditation on Tuesday morning 11 June. And enjoy the unique scenery of the most beautiful park of Rotterdam near the Euromast.

  Time 07.30 – 08.30
  Address Euromast, Parkhaven 20, 3016 GM Rotterdam

• 08:00 - 08:50
  Meet the experts | Health economics, pharmacovigilance & reading the IB

  WHO Step: 5-6

  • 08:00 - 08:50
    Meet the expert 4 | How to perform a health economic study
  • 08:00 - 08:50
    Meet the expert 5 | How to make and review an IB
  • 08:00 - 08:50
    Meet the expert 6 | How to prove causality in pharmacovigilance in early and late/post marketing research
  • 08:00 - 08:50
    Meet the expert 7 | Drug-drug interaction management with investigational medicinal products: can we do better?
• 08:00 - 09:00
  Registration
• 09:00 - 10:00
  Plenary Session | Access to health care & the Green Deal in drug therapy

  WHO Step: 5

  • 09:30 - 10:00
    How to reduce environmental impact of pharmaceuticals (Green Deal of EU)
• 10:00 - 10:10
  Poster Pitches

  WHO Step: 5-6

  Abstracts

  Long-Term Antibody Responses to COVAXIN and COVISHIELD Vaccines in Rheumatoid Arthritis Patients and healthy control population

  Submitted by: Madhavi Eerike

  “Doctor, is your patient at risk for prescribing errors?” Identifying eligible patients for in-hospital pharmacotherapeutic stewardship: A matched case-control study

  Submitted by: Rashudy Mahomedradja

  A good start is half the battle: antibiotic IV line residuals in the intensive care unit

  Submitted by: Dorian Vanneste

  Disproportionality analysis of neurological adverse reactions to COVID-19 vaccines: insights from Eudravigilance

  Submitted by: Arturo Gomez

  Is the acceptance of pharmacist interventions from a specialized pharmacist working on the ward higher than from a non-specialized pharmacist?

  Submitted by: Sarah Wilkes

• 10:10 - 10:30
  Coffee Break
• 10:30 - 12:30
  Parallel Sessions 12-13-14

  WHO Step: 5

  • 10:30 - 12:30
    Parallel 12

    • 10:30 - 11:00
      Student Run Clinics in Pharmacotherapy Education
    • 11:00 - 11:20
      AI and Education
    • 11:20 - 11:50
      Planetary Health Education in Prescribing

    Abstracts

    Building a teaching program to harmonize and optimize clinical at the Eurpean level: The CONSCIOUS curriculum project

    Submitted by: Stephane Mouly

    Toxicology education: an innovative interprofessional simulation training

    Submitted by: Rozita Abdolrahimi Raeni

    Serious Gaming as a training tool for recognition of adverse drug reactions in personalised medicine

    Submitted by: Katja Just

    Comparing attitudes to and performance in the UK Prescribing Safety Assessment among different student cohorts in University College Dublin, Ireland

    Submitted by: Helen C. Gallagher

  • 10:30 - 12:30
    Parallel 13

    Abstracts

    Implementing dose bands: a new cost saving, efficient and sustainable method for preparation of chemotherapy agents

    Submitted by: Helle-Brit Fiebrich-Westra

    Cost-Aware Prescribing Study: A Randomized Trial Investigating the Impact of Regular Feedback on Physician Prescription Behaviour

    Submitted by: Anne-Sophie Klein Gebbink

    Implementation of a multiple criteria decision analysis framework to support decisions for individual access to medicines

    Submitted by: Montse Gasol

    Patient access to cell and gene therapies in Europe: a scoping review of impeding factors

    Submitted by: Christine Van Hattem

    Assessment of Single-Dose Vial Disposal Practices in Cancer Patients: Financial and Environmental Implications in an Island Hospital Pharmacy

    Submitted by: Zohreh Safipour

  • 10:30 - 12:30
    Parallel 14

    • 10:30 - 12:30
      Implementation of Pgx

      Improving bad habits by implementing an interventional project of fluid stewardship according to NICE guidelines

      Submitted by

      Amal Zoubi

      Derivation and validation of a prediction rule for the presence of resistant Enterobacteriaceae in patients hospitalized for a community-acquired UTI

      Submitted by

      Luis Rojas

      The development of practice recommendations for P-glycoprotein-mediated drug-drug interactions

      Submitted by

      Leonie Bogaard

      Which prescribing cascades are relevant for clinical practice? A mixed-method study

      Submitted by

      Jacqueline Hugtenburg

      Therapeutic recommendations for attention deficit hyperactivity disorders: is there any alternative to clinical practice guidelines?

      Submitted by

      David Ramírez Saco

      Effectiveness of Rational Therapeutics & Prescribing Skills Course for Undergraduate Medical Students

      Submitted by

      Santosh Kumar
• 12:30 - 14:00
  Lunch Poster Session

  WHO Step: 5-6

• 14:00 - 16:00
  Parallel Sessions 15-16-17

  WHO Step: 6

  • 14:00 - 16:00
    Parallel 15

    Abstracts

    Two overdoses related to the same medication error in an academic clinical trial in oncology

    Submitted by: Laure PEYRO-SAINT-PAUL

    Sodium Polystyrene Sulfonate and The Risk of Hypertension

    Submitted by: Ophir Lavon

    Surveillance of Antimicrobial Drug Consumption in Hospitals in Kazakhstan: A Pilot Project

    Submitted by: Nurgul Aldiyarova

    Health Professional barriers and facilitators to discontinuing antidepressant use: a systematic review and thematic synthesis

    Submitted by: Ellen Van Leeuwen

    Compassionate Use of Drugs in Hospitalized Patients during the First COVID-19 Wave: A Global Country-Level Meta-Analysis of Cohort Studies

    Submitted by: Claudina MICHAL-TEITELBAUM

    Recent Research brought advances for Colistin TDM

    Submitted by: Jitka Rychlickova

  • 14:00 - 16:00
    Parallel 16

    • 14:00 - 16:00
      Precision therapy in organ transplant patients - the use of TDM and AI

      The Impact on Migraine Treatment Needs of Biological Prophylaxis. Real World Data.

      Submitted by

      Adomas Danilevicius

      Impact of antithrombotic therapy on thrombotic and bleeding complications after elective endovascular repair of abdominal aortic aneurysms

      Submitted by

      Josephine Kranendonk

      Real world effectiveness of durvalumab in stage III unresectable non-small cell lung cancer: what is the role of PD-L1 expression?

      Submitted by

      Hanieh Abedian Kalkhoran

      Exposure-toxicity relationship of pazopanib in real-world adult metastatic renal cell carcinoma and soft tissue sarcoma patients

      Submitted by

      Zhiyuan Tan
  • 14:00 - 16:00
    Parallel 17

    Abstracts

    Inter-rater agreement regarding detection of STOPP criteria in older primary care patients – a comparison between explicit and implicit criteria

    Submitted by: Naldy Parodi López

    Comparison of renal function estimating equations as surrogates for amoxicillin clearance in hospitalized older patients

    Submitted by: Arnaud De Clercq

    ANALYSIS OF DRUG INTERACTIONS POTENTIALLY RESULTING IN FALLS IN ELDERLY PATIENTS

    Submitted by: Ekaterina Ilyina

    Use of DPP4-inhibitors, GLP-1 analogues and SGLT2-inhibitors in the treatment of frail older people with type 2 diabetes

    Submitted by: Petra Spies

    Older patients’ experiences and needs regarding in-hospital pharmacotherapeutic care during admission and after discharge: a qualitative study

    Submitted by: Eline Engelen

    Nocturnal safety of daridorexant (QUVIVIQ®) in healthy elderly subjects, a dual orexin receptor antagonist

    Submitted by: Massimo Magliocca

• 16:00 - 16:30
  Tea Break
• 16:30 - 17:30
  Award lectures and Closing Ceremony